Decibel Therapeutics (DBTX) IPO Opens 18% Higher

Today's IPO for Decibel Therapeutics (NASDAQ: DBTX) opened for trading at $21.20 after pricing 7,062,000 shares of its common stock at a price to the public of $18.00 per share.

Citigroup, SVB Leerink, BMO Capital Markets and Barclays are acting as joint book-running managers for the offering.

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.

You May Also Be Interested In

• YPF Energía Eléctrica S.A. files for proposed NYSE IPO
• Samos Energy raises $230M in NYSE IPO for energy acquisitions
• Sk Hynix Opens At $170, IPO Priced At $149